| (+)-Theta-cypermethrin |
|
|
|
|
|
|
|
|
|
|
|
| (R)-LW-Srci-8 |
|
|
|
|
|
|
|
|
|
|
|
| 1-Naphthyl PP1 |
|
|
|
|
|
|
|
|
|
|
99.36% |
| 1-Naphthyl PP1 hydrochloride |
|
|
|
|
|
|
|
|
|
|
99.83% |
| 1-NM-PP1 |
|
|
|
|
|
|
|
|
|
|
98.93% |
| 15-deoxy-Δ12,14-Prostaglandin D2 |
|
|
|
|
|
|
|
|
|
|
98.0% |
| 15-deoxy-Δ12,14-Prostaglandin D2-d4 |
|
|
|
|
|
|
|
|
|
|
|
| 2,3,4,6,8-Pentahydroxy-1-methylxanthone |
|
|
|
|
|
|
|
|
|
|
|
| 3'-Demethylnobiletin |
|
|
|
|
|
|
|
|
|
|
99.98% |
| 5-O-Methylvisammioside |
|
|
|
|
|
|
|
|
|
|
99.90% |
| 5-POHSA |
|
|
|
|
|
|
|
|
|
|
|
| 7-Hydroxy-4H-chromen-4-one |
|
|
|
|
|
|
|
|
|
|
99.85% |
| 7α-Hydroxycholesterol |
|
|
|
|
|
|
|
|
|
|
99.99% |
| A 419259 |
|
|
|
|
|
|
|
|
|
|
99.88% |
| A 419259 |
|
|
|
|
|
|
|
|
|
|
|
| A 419259 trihydrochloride |
|
|
|
|
|
|
|
|
|
|
98.28% |
| A-420983 |
|
|
|
|
|
|
|
|
|
|
|
| A-770041 |
|
|
|
|
|
|
|
|
|
|
99.89% |
| Ac-PPPHPHARIK-NH2 |
|
|
|
|
|
|
|
|
|
|
|
| Ac-Tyr(PO3H2)-Glu-Glu-Ile-Glu-OH |
|
|
|
|
|
|
|
|
|
|
|
| Ac-Tyr(PO3H2)-Glu-Glu-Ile-Glu-OH TFA |
|
|
|
|
|
|
|
|
|
|
|
| AD1058 |
|
|
|
|
|
|
|
|
|
|
98.04% |
| AD57 |
|
|
|
|
|
|
|
|
|
|
98.27% |
| AD57 hydrochloride |
|
|
|
|
|
|
|
|
|
|
|
| AD80 |
|
|
|
|
|
|
|
|
|
|
99.88% |
| AG01 |
|
|
|
|
|
|
|
|
|
|
95.10% |
| AMG-47a |
|
|
|
|
|
|
|
|
|
|
99.19% |
| Aminogenistein |
|
|
|
|
|
|
|
|
|
|
|
| Antiallergic agent-1 |
|
|
|
|
|
|
|
|
|
|
|
| Antiangiogenic agent 3 |
|
|
|
|
|
|
|
|
|
|
|
| Antifibrotic agent 1 |
|
|
|
|
|
|
|
|
|
|
|
| Antiproliferative agent-54 |
|
|
|
|
|
|
|
|
|
|
|
| AP 24149 |
|
|
|
|
|
|
|
|
|
|
|
| AP-22161 |
|
|
|
|
|
|
|
|
|
|
|
| AP22408 |
|
|
|
|
|
|
|
|
|
|
|
| Apatinib-d8 free base |
|
|
|
|
|
|
|
|
|
|
92.03% |
| ARN25699 |
|
|
|
|
|
|
|
|
|
|
|
| AZD0424 |
|
|
|
|
|
|
|
|
|
|
|
| AZM475271 |
|
|
|
|
|
|
|
|
|
|
99.89% |
| BCR-ABL-IN-13 |
|
|
|
|
|
|
|
|
|
|
99.86% |
| Birelentinib |
|
|
|
|
|
|
|
|
|
|
|
| BJ-2302 |
|
|
|
|
|
|
|
|
|
|
|
| BLK degrader 1 |
|
|
|
|
|
|
|
|
|
|
98.94% |
| BMS-243117 |
|
|
|
|
|
|
|
|
|
|
|
| BMS-279700 |
|
|
|
|
|
|
|
|
|
|
|
| Bosutinib |
|
|
|
|
|
|
|
|
|
|
99.85% |
| Bosutinib hydrate |
|
|
|
|
|
|
|
|
|
|
99.97% |
| Bosutinib-d8 |
|
|
|
|
|
|
|
|
|
|
|
| BT424 |
|
|
|
|
|
|
|
|
|
|
98.89% |
| BTK-IN-45 |
|
|
|
|
|
|
|
|
|
|
|
| BTK-IN-48 |
|
|
|
|
|
|
|
|
|
|
|
| BY13 |
|
|
|
|
|
|
|
|
|
|
|
| Caffeic acid-pYEEIE |
|
|
|
|
|
|
|
|
|
|
|
| Caffeic acid-pYEEIE TFA |
|
|
|
|
|
|
|
|
|
|
98.47% |
| CCT241161 |
|
|
|
|
|
|
|
|
|
|
99.77% |
| CGP062464 |
|
|
|
|
|
|
|
|
|
|
|
| CGP77675 |
|
|
|
|
|
|
|
|
|
|
99.46% |
| CGP77675 hydrate |
|
|
|
|
|
|
|
|
|
|
|
| CH6953755 |
|
|
|
|
|
|
|
|
|
|
99.75% |
| Chemerin15 |
|
|
|
|
|
|
|
|
|
|
99.65% |
| CHMFL-ABL-053 |
|
|
|
|
|
|
|
|
|
|
|
| Chrysotoxine |
|
|
|
|
|
|
|
|
|
|
99.52% |
| Cisplatin/Dasatinib prodrug-1 |
|
|
|
|
|
|
|
|
|
|
|
| Convulxin |
|
|
|
|
|
|
|
|
|
|
|
| CpCDPK1/TgCDPK1-IN-1 |
|
|
|
|
|
|
|
|
|
|
|
| CSK substrate |
|
|
|
|
|
|
|
|
|
|
|
| CSK-IN-1 |
|
|
|
|
|
|
|
|
|
|
98.04% |
| cSRC/BCR-ABL-IN-1 |
|
|
|
|
|
|
|
|
|
|
|
| DA5-HTL |
|
|
|
|
|
|
|
|
|
|
98.69% |
| Damnacanthal |
|
|
|
|
|
|
|
|
|
|
99.40% |
| DAS-5-oCRBN |
|
|
|
|
|
|
|
|
|
|
99.21% |
| Dasatinib |
|
|
|
|
|
|
|
|
|
|
|
| Dasatinib (GMP Like) |
|
|
|
|
|
|
|
|
|
|
|
| DB-0646 |
|
|
|
|
|
|
|
|
|
|
98.0% |
| DB-3-291 |
|
|
|
|
|
|
|
|
|
|
99.08% |
| DB0662 |
|
|
|
|
|
|
|
|
|
|
99.66% |
| DC-Srci-6649 |
|
|
|
|
|
|
|
|
|
|
|
| DFCI-002-06 |
|
|
|
|
|
|
|
|
|
|
|
| DGY-06-116 |
|
|
|
|
|
|
|
|
|
|
98.62% |
| eCF506 |
|
|
|
|
|
|
|
|
|
|
99.09% |
| eCF506-d5 |
|
|
|
|
|
|
|
|
|
|
|
| Elzovantinib |
|
|
|
|
|
|
|
|
|
|
99.93% |
| ENMD-2076 |
|
|
|
|
|
|
|
|
|
|
99.99% |
| ENMD-2076 Tartrate |
|
|
|
|
|
|
|
|
|
|
99.66% |
| EphB4-IN-1 |
|
|
|
|
|
|
|
|
|
|
|
| EPQpYEEIPIYL |
|
|
|
|
|
|
|
|
|
|
99.49% |
| Excisanin A |
|
|
|
|
|
|
|
|
|
|
|
| FAK inhibitor 7 |
|
|
|
|
|
|
|
|
|
|
|
| Fenlean |
|
|
|
|
|
|
|
|
|
|
99.56% |
| FITC-amide-C2 Lck inhibitor 2 |
|
|
|
|
|
|
|
|
|
|
|
| FRK Recombinant Human Active Protein Kinase |
|
|
|
|
|
|
|
|
|
|
|
| FYN Y531F Recombinant Human Active Protein Kinase |
|
|
|
|
|
|
|
|
|
|
|
| Fyn-IN-1 |
|
|
|
|
|
|
|
|
|
|
|
| Ganglioside GM2 |
|
|
|
|
|
|
|
|
|
|
98.0% |
| GLPG3312 |
|
|
|
|
|
|
|
|
|
|
98.63% |
| Grb2 SH2 domain inhibitor 1 TFA |
|
|
|
|
|
|
|
|
|
|
99.62% |
| GSK2646264 |
|
|
|
|
|
|
|
|
|
|
99.74% |
| GW297361 |
|
|
|
|
|
|
|
|
|
|
98.05% |
| Hck-IN-1 |
|
|
|
|
|
|
|
|
|
|
98.10% |
| Hck-IN-2 |
|
|
|
|
|
|
|
|
|
|
|
| Hck-IN-3 |
|
|
|
|
|
|
|
|
|
|
|
| Herbimycin B |
|
|
|
|
|
|
|
|
|
|
|
| HG-7-85-01 |
|
|
|
|
|
|
|
|
|
|
98.14% |
| Hibarimicin A |
|
|
|
|
|
|
|
|
|
|
|
| Hibarimicin B |
|
|
|
|
|
|
|
|
|
|
|
| Hibarimicin C |
|
|
|
|
|
|
|
|
|
|
|
| Hibarimicin D |
|
|
|
|
|
|
|
|
|
|
|
| Hibarimicin G |
|
|
|
|
|
|
|
|
|
|
|
| HIV-IN-6 |
|
|
|
|
|
|
|
|
|
|
98.35% |
| HL403 |
|
|
|
|
|
|
|
|
|
|
|
| HPK1-IN-2 dihydrochloride |
|
|
|
|
|
|
|
|
|
|
98.03% |
| HPK1-IN-61 |
|
|
|
|
|
|
|
|
|
|
|
| Hydroxy-PP |
|
|
|
|
|
|
|
|
|
|
99.66% |
| Hydroxymethyl dasatinib |
|
|
|
|
|
|
|
|
|
|
99.92% |
| IGF-1R/SRC-IN-1 |
|
|
|
|
|
|
|
|
|
|
99.86% |
| iHCK-37 |
|
|
|
|
|
|
|
|
|
|
99.52% |
| IL13Rα2 D1 |
|
|
|
|
|
|
|
|
|
|
99.17% |
| ISO24 |
|
|
|
|
|
|
|
|
|
|
|
| JNJ-49095397 |
|
|
|
|
|
|
|
|
|
|
99.55% |
| JP-153 |
|
|
|
|
|
|
|
|
|
|
99.45% |
| K882 |
|
|
|
|
|
|
|
|
|
|
|
| KB SRC 4 |
|
|
|
|
|
|
|
|
|
|
99.22% |
| KIN-8194 |
|
|
|
|
|
|
|
|
|
|
99.26% |
| KL-1156 |
|
|
|
|
|
|
|
|
|
|
|
| KX1-004 |
|
|
|
|
|
|
|
|
|
|
99.75% |
| KX2-361 |
|
|
|
|
|
|
|
|
|
|
99.09% |
| Larixol |
|
|
|
|
|
|
|
|
|
|
95.52% |
| Larixyl acetate |
|
|
|
|
|
|
|
|
|
|
99.44% |
| LCB 03-0110 |
|
|
|
|
|
|
|
|
|
|
|
| LCB 03-0110 dihydrochloride |
|
|
|
|
|
|
|
|
|
|
|
| Lck degrader-1 |
|
|
|
|
|
|
|
|
|
|
|
| LCK degrader-2 |
|
|
|
|
|
|
|
|
|
|
|
| LCK degrader-3 |
|
|
|
|
|
|
|
|
|
|
|
| Lck Inhibitor |
|
|
|
|
|
|
|
|
|
|
99.65% |
| Lck inhibitor 2 |
|
|
|
|
|
|
|
|
|
|
99.73% |
| Lck Inhibitor III |
|
|
|
|
|
|
|
|
|
|
|
| LCK ligand-1 |
|
|
|
|
|
|
|
|
|
|
|
| Lck-IN-1 |
|
|
|
|
|
|
|
|
|
|
98.54% |
| Lck-IN-2 |
|
|
|
|
|
|
|
|
|
|
|
| Lck-IN-3 |
|
|
|
|
|
|
|
|
|
|
|
| Lck-IN-4 |
|
|
|
|
|
|
|
|
|
|
|
| Lck-IN-5 |
|
|
|
|
|
|
|
|
|
|
98.09% |
| Lck-IN-6 |
|
|
|
|
|
|
|
|
|
|
|
| LDDN-0003499 |
|
|
|
|
|
|
|
|
|
|
|
| Lyn peptide inhibitor |
|
|
|
|
|
|
|
|
|
|
99.35% |
| Lyn peptide inhibitor TFA |
|
|
|
|
|
|
|
|
|
|
|
| Lyn-IN-1 |
|
|
|
|
|
|
|
|
|
|
98.07% |
| Lysoganglioside-GM1 ammonium |
|
|
|
|
|
|
|
|
|
|
|
| Lysoganglioside-GM1 potassium |
|
|
|
|
|
|
|
|
|
|
|
| mG2N001 |
|
|
|
|
|
|
|
|
|
|
|
| MLS-2384 free base |
|
|
|
|
|
|
|
|
|
|
|
| MNS |
|
|
|
|
|
|
|
|
|
|
|
| Momordicine I |
|
|
|
|
|
|
|
|
|
|
97.0% |
| MRT-7612 |
|
|
|
|
|
|
|
|
|
|
|
| Multi kinase ligand 4 |
|
|
|
|
|
|
|
|
|
|
|
| Multi-kinase-IN-1 |
|
|
|
|
|
|
|
|
|
|
|
| Multi-kinase-IN-11 |
|
|
|
|
|
|
|
|
|
|
|
| Multi-kinase-IN-12 |
|
|
|
|
|
|
|
|
|
|
|
| Multi-kinase-IN-2 |
|
|
|
|
|
|
|
|
|
|
|
| Lavendustin C |
|
|
|
|
|
|
|
|
|
|
98.17% |
| N-Acetyl-O-phosphono-Tyr-Glu dipentylamide |
|
|
|
|
|
|
|
|
|
|
|
| N-Deshydroxyethyl Dasatinib-C3-NH2 |
|
|
|
|
|
|
|
|
|
|
|
| NEO212 |
|
|
|
|
|
|
|
|
|
|
|
| Neopterin |
|
|
|
|
|
|
|
|
|
|
99.95% |
| Osteogenic Growth Peptide (10-14) |
|
|
|
|
|
|
|
|
|
|
99.51% |
| p60c-src Substrate |
|
|
|
|
|
|
|
|
|
|
|
| p60c-src substrate II |
|
|
|
|
|
|
|
|
|
|
|
| p60c-src substrate II, phosphorylated |
|
|
|
|
|
|
|
|
|
|
|
| P60v-src(137-157) |
|
|
|
|
|
|
|
|
|
|
|
| Papaveroline |
|
|
|
|
|
|
|
|
|
|
|
| Papaveroline hydrochloride |
|
|
|
|
|
|
|
|
|
|
99.04% |
| PD-089828 |
|
|
|
|
|
|
|
|
|
|
98.07% |
| PD-161570 |
|
|
|
|
|
|
|
|
|
|
99.82% |
| PD166326 |
|
|
|
|
|
|
|
|
|
|
99.99% |
| PD173952 |
|
|
|
|
|
|
|
|
|
|
99.58% |
| PD173955 |
|
|
|
|
|
|
|
|
|
|
99.12% |
| PD180970 |
|
|
|
|
|
|
|
|
|
|
99.27% |
| PDD-87 |
|
|
|
|
|
|
|
|
|
|
|
| Peruvoside |
|
|
|
|
|
|
|
|
|
|
99.32% |
| PF 477736 |
|
|
|
|
|
|
|
|
|
|
99.04% |
| pFYN peptide |
|
|
|
|
|
|
|
|
|
|
|
| PP1 |
|
|
|
|
|
|
|
|
|
|
99.57% |
| PP121 |
|
|
|
|
|
|
|
|
|
|
99.51% |
| PP2 |
|
|
|
|
|
|
|
|
|
|
98.34% |
| PP2 Analog |
|
|
|
|
|
|
|
|
|
|
|
| PP487 |
|
|
|
|
|
|
|
|
|
|
|
| PP58 |
|
|
|
|
|
|
|
|
|
|
98.70% |
| Pro-Dasatinib |
|
|
|
|
|
|
|
|
|
|
|
| proMMP-9 inhibitor-3c |
|
|
|
|
|
|
|
|
|
|
|
| Propionyl-L-carnitine |
|
|
|
|
|
|
|
|
|
|
95.0% |
| PROTAC AR Degrader-12 |
|
|
|
|
|
|
|
|
|
|
|
| PROTAC TG2 Degrader-3 |
|
|
|
|
|
|
|
|
|
|
|
| Protein kinase inhibitor 11 |
|
|
|
|
|
|
|
|
|
|
98.28% |
| Protein kinase inhibitor 13 |
|
|
|
|
|
|
|
|
|
|
|
| PRT062607 acetate |
|
|
|
|
|
|
|
|
|
|
99.83% |
| PRT062607 Hydrochloride |
|
|
|
|
|
|
|
|
|
|
98.07% |
| pYEEI |
|
|
|
|
|
|
|
|
|
|
99.01% |
| Pyridostatin |
|
|
|
|
|
|
|
|
|
|
96.03% |
| Pyridostatin hydrochloride |
|
|
|
|
|
|
|
|
|
|
99.95% |
| Pyridostatin TFA |
|
|
|
|
|
|
|
|
|
|
99.17% |
| Pyridostatin trihydrochloride |
|
|
|
|
|
|
|
|
|
|
99.85% |
| Rebastinib |
|
|
|
|
|
|
|
|
|
|
99.74% |
| Rhodomycin A |
|
|
|
|
|
|
|
|
|
|
|
| RK-20448 |
|
|
|
|
|
|
|
|
|
|
99.38% |
| RK-24466 |
|
|
|
|
|
|
|
|
|
|
99.91% |
| RR-SRC |
|
|
|
|
|
|
|
|
|
|
|
| Saracatinib difumarate |
|
|
|
|
|
|
|
|
|
|
99.93% |
| SB 220025 |
|
|
|
|
|
|
|
|
|
|
99.90% |
| SB 220025 (tri(hydrochloride)) |
|
|
|
|
|
|
|
|
|
|
|
| SB1-G-187 |
|
|
|
|
|
|
|
|
|
|
98.70% |
| Scr-IN-1 |
|
|
|
|
|
|
|
|
|
|
|
| Scr-IN-2 |
|
|
|
|
|
|
|
|
|
|
|
| SI-2 |
|
|
|
|
|
|
|
|
|
|
|
| Si306 |
|
|
|
|
|
|
|
|
|
|
|
| SIK1-IN-1 |
|
|
|
|
|
|
|
|
|
|
|
| SJ11646 |
|
|
|
|
|
|
|
|
|
|
|
| SJ45566 |
|
|
|
|
|
|
|
|
|
|
98.41% |
| SKLB-C05 |
|
|
|
|
|
|
|
|
|
|
|
| SKLB646 |
|
|
|
|
|
|
|
|
|
|
|
| SKS-927 |
|
|
|
|
|
|
|
|
|
|
|
| SM1-71 |
|
|
|
|
|
|
|
|
|
|
96.09% |
| Squarunkin A |
|
|
|
|
|
|
|
|
|
|
99.49% |
| Squarunkin A hydrochloride |
|
|
|
|
|
|
|
|
|
|
|
| Src Inhibitor 1 |
|
|
|
|
|
|
|
|
|
|
99.97% |
| Src Inhibitor 3 |
|
|
|
|
|
|
|
|
|
|
|
| Src Inhibitor 4 |
|
|
|
|
|
|
|
|
|
|
|
| SRC-3-IN-1 |
|
|
|
|
|
|
|
|
|
|
|
| SRC-3-IN-2 |
|
|
|
|
|
|
|
|
|
|
96.32% |
| Src-ZAP70 Recombinant Human Active Protein Kinase |
|
|
|
|
|
|
|
|
|
|
|
| SRT6 |
|
|
|
|
|
|
|
|
|
|
|
| STAT-3/c-Src-IN-1 |
|
|
|
|
|
|
|
|
|
|
|
| SU6656 |
|
|
|
|
|
|
|
|
|
|
98.30% |
| T338C Src-IN-1 |
|
|
|
|
|
|
|
|
|
|
|
| T338C Src-IN-2 |
|
|
|
|
|
|
|
|
|
|
98.41% |
| Tesevatinib |
|
|
|
|
|
|
|
|
|
|
99.41% |
| Tesevatinib tosylate |
|
|
|
|
|
|
|
|
|
|
|
| TG 100572 |
|
|
|
|
|
|
|
|
|
|
|
| TG 100572 Hydrochloride |
|
|
|
|
|
|
|
|
|
|
98.76% |
| TG 100801 |
|
|
|
|
|
|
|
|
|
|
98.61% |
| TG 100801 Hydrochloride |
|
|
|
|
|
|
|
|
|
|
|
| TG-100435 |
|
|
|
|
|
|
|
|
|
|
|
| TG53 |
|
|
|
|
|
|
|
|
|
|
98.14% |
| TGF-βRI inhibitor 3 |
|
|
|
|
|
|
|
|
|
|
99.16% |
| Tirbanibulin |
|
|
|
|
|
|
|
|
|
|
99.45% |
| Tirbanibulin dihydrochloride |
|
|
|
|
|
|
|
|
|
|
98.02% |
| Tirbanibulin Mesylate |
|
|
|
|
|
|
|
|
|
|
99.94% |
| TL02-59 |
|
|
|
|
|
|
|
|
|
|
99.86% |
| TL02-59 dihydrochloride |
|
|
|
|
|
|
|
|
|
|
|
| TL02-59-d5 |
|
|
|
|
|
|
|
|
|
|
|
| TL13-68 |
|
|
|
|
|
|
|
|
|
|
98.31% |
| Tolimidone |
|
|
|
|
|
|
|
|
|
|
99.98% |
| TOP1210 |
|
|
|
|
|
|
|
|
|
|
|
| TOP1288 |
|
|
|
|
|
|
|
|
|
|
|
| TOP1362 |
|
|
|
|
|
|
|
|
|
|
|
| TX-1123 |
|
|
|
|
|
|
|
|
|
|
|
| TX-1918 |
|
|
|
|
|
|
|
|
|
|
|
| Tyrosine Kinase Peptide 1 |
|
|
|
|
|
|
|
|
|
|
|
| Tyrosine Kinase Peptide 1 acetate |
|
|
|
|
|
|
|
|
|
|
99.51% |
| Tyrosine kinase-IN-11 |
|
|
|
|
|
|
|
|
|
|
98.75% |
| UM-164 |
|
|
|
|
|
|
|
|
|
|
98.69% |
| Velzatinib |
|
|
|
|
|
|
|
|
|
|
99.40% |
| VI 16832 |
|
|
|
|
|
|
|
|
|
|
99.09% |
| WH-4-023 |
|
|
|
|
|
|
|
|
|
|
|
| WH-4-023 |
|
|
|
|
|
|
|
|
|
|
99.87% |
| XL228 |
|
|
|
|
|
|
|
|
|
|
99.64% |
| YH-306 |
|
|
|
|
|
|
|
|
|
|
98.34% |
| β-Hydroxyisovalerylshikonin |
|
|
|
|
|
|
|
|
|
|
99.83% |
| Notoginsenoside R2 |
|
|
|
|
|
|
|
|
|
|
99.80% |
| Notoginsenoside Fe |
|
|
|
|
|
|
|
|
|
|
99.99% |
| Hexachlorobenzene |
|
|
|
|
|
|
|
|
|
|
98.82% |
| Bosutinib-13C,d3 |
|
|
|
|
|
|
|
|
|
|
|
| Pelitinib-d6 |
|
|
|
|
|
|
|
|
|
|
|
| Pelitinib |
|
|
|
|
|
|
|
|
|
|
98.52% |
| Saracatinib |
|
|
|
|
|
|
|
|
|
|
99.23% |
| Saracatinib-d3 |
|
|
|
|
|
|
|
|
|
|
|
| 2-Hydroxy-3-methylanthraquinone |
|
|
|
|
|
|
|
|
|
|
98.67% |
| Bafetinib |
|
|
|
|
|
|
|
|
|
|
99.02% |
| Isomaltulose monohydrate |
|
|
|
|
|
|
|
|
|
|
|
| Ponatinib-d8 |
|
|
|
|
|
|
|
|
|
|
99.16% |
| Ponatinib |
|
|
|
|
|
|
|
|
|
|
99.67% |
| Ponatinib hydrochloride |
|
|
|
|
|
|
|
|
|
|
99.76% |
| Masitinib mesylate |
|
|
|
|
|
|
|
|
|
|
99.98% |
| Atractylenolide II |
|
|
|
|
|
|
|
|
|
|
99.89% |
| (-)-Asarinin |
|
|
|
|
|
|
|
|
|
|
99.90% |
| Plantamajoside |
|
|
|
|
|
|
|
|
|
|
99.80% |
| Dasatinib |
|
|
|
|
|
|
|
|
|
|
99.83% |
| Dasatinib-d8 |
|
|
|
|
|
|
|
|
|
|
99.15% |
| Dasatinib-d4 |
|
|
|
|
|
|
|
|
|
|
97.54% |
| Dasatinib monohydrate |
|
|
|
|
|
|
|
|
|
|
99.58% |
| Dasatinib hydrochloride |
|
|
|
|
|
|
|
|
|
|
99.31% |
| Scutellarein |
|
|
|
|
|
|
|
|
|
|
99.39% |
| Masitinib |
|
|
|
|
|
|
|
|
|
|
99.66% |